Drug delays type 1 diabetes in people at high risk

(NIH/National Institute of Diabetes and Digestive and Kidney Diseases) A treatment affecting the immune system effectively slowed the progression to clinical type 1 diabetes in high risk individuals, according to findings from National Institutes of Health-funded research. The study is the first to show that clinical type 1 diabetes can be delayed by two or more years among people who are at high risk.